Publications by authors named "Matthew Ames"

99Publications

Pharmacokinetics of dacarbazine (DTIC) in pregnancy.

Cancer Chemother Pharmacol 2018 03 5;81(3):455-460. Epub 2018 Jan 5.

Department of Pharmacy, University of Washington, 1959 NE Pacific Street, Seattle, WA, 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3511-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828904PMC
March 2018

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

J Clin Oncol 2017 Oct 30;35(30):3391-3400. Epub 2017 Aug 30.

Matthew P. Goetz, Vera J. Suman, Joel M. Reid, Don W. Northfelt, Michael A. Mahr, Andrew T. Ralya, Mary Kuffel, Sarah A. Buhrow, Stephanie L. Safgren, Renee M. McGovern, John Black, Travis Dockter, Tufia Haddad, Charles Erlichman, Alex A. Adjei, Dan Visscher, Benjamin R. Kipp, Minetta C. Liu, John R. Hawse, Matthew M. Ames, and James N. Ingle, Mayo Clinic, Rochester, MN; Zachary R. Chalmers and Garrett Frampton, Foundation Medicine, Cambridge, MA; and John R. Hawse, James H. Doroshow, Jerry M. Collins, and Howard Streicher, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.3246
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.3246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648176PMC
October 2017

Comparative Metabolism of Batracylin (NSC 320846) and N-acetylbatracylin (NSC 611001) Using Human, Dog, and Rat Preparations .

J Drug Metab Toxicol 2016 Jun 8;7(2). Epub 2016 May 8.

Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4172/2157-7609.1000203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948755PMC
June 2016

Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.

Cancer Genet 2015 Jul-Aug;208(7-8):374-81. Epub 2015 Apr 14.

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA; Mayo Clinic Cancer Center, Rochester, MN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2015.04.002DOI Listing
October 2015

Life without limbs: Technology to the rescue.

Prosthet Orthot Int 2016 Aug 27;40(4):517-21. Epub 2015 Apr 27.

Mater Private Hospital Brisbane, South Brisbane, QLD, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0309364615579316DOI Listing
August 2016

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.

Pharmacogenet Genomics 2015 Apr;25(4):157-63

Departments of aOncology bMolecular Pharmacology and Experimental Therapeutics cBiostatistics dLaboratory Medicine, Mayo Clinic, Rochester, Minnesota eDepartment of Hematology and Oncology, Mayo Clinic, Scottsdale, Arizona fCambridge Isotope Laboratories Inc. gPhysical Sciences Inc., Andover, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356640PMC
April 2015

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

J Natl Cancer Inst 2014 Dec 8;107(2). Epub 2014 Dec 8.

Department of Oncology (MPG, MMA, JNI), Department of Health Sciences Research (VJS, KRK), and Department of Molecular Pharmacology and Experimental Therapeutics (MPG, SLS, MK, MMA), Mayo Clinic, Rochester, MN; Department of Genetics, University of North Carolina, Chapel Hill, NC (GOS, CMP); Center for Personalized Therapeutics, University of Chicago, Chicago, IL (YN, NJC, MJR); Foundation Medicine Inc., Cambridge, MA (JXS, PJS, VAM, JSR, RY); Novartis Pharmaceuticals Corporation, East Hanover, NJ (DC); Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY (JSR); Division of Hematology/Oncology, Vanderbilt University, Nashville, TN (HG); Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (AMGA, OB); Department Breast Cancer Susceptibility and Pharmacogenomics, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, University Tuebingen, German Cancer Consortium (DKTK) and German Cancer Research (DKTK), Heidelberg, Germany (HB).Current affiliation of H. Gomez: Departamento de Medicina Oncologica, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565524PMC
December 2014

Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993).

Cancer Chemother Pharmacol 2014 Jun 24;73(6):1137-46. Epub 2014 Apr 24.

Department of Oncology, Division of Oncology Research, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2447-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392893PMC
June 2014

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.

BMC Res Notes 2014 Apr 23;7:256. Epub 2014 Apr 23.

Cancer Center and Departments of Cell Biology and Biochemistry, Pharmacology and Neuroscience, Pediatrics, and Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, STOP 9445 79430 Lubbock, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-0500-7-256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006848PMC
April 2014

Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.

Toxicol Pathol 2014 Dec 26;42(8):1188-96. Epub 2014 Mar 26.

Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0192623314525688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177029PMC
December 2014

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.

Invest New Drugs 2013 Oct 31;31(5):1251-6. Epub 2013 Mar 31.

Division of Medical Oncology, Mayo Clinic College of Medicine, Mayo Clinic, Gonda 19, 200 First Street, S.W, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9946-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929968PMC
October 2013

Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.

Pancreas 2013 Apr;42(3):411-21

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0b013e31826cb243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594087PMC
April 2013

Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents.

Anticancer Agents Med Chem 2012 Nov;12(9):1117-31

MediChem Research, Inc., 2501 Davey Road, Woodridge, Illinois 60517, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187152012803529628DOI Listing
November 2012

Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.

J Drug Metab Toxicol 2011 Feb;2(107):1-10

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4172/2157-7609.1000107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144579PMC
February 2011

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

Invest New Drugs 2011 Oct 12;29(5):1004-12. Epub 2010 May 12.

Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9447-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545439PMC
October 2011

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Cancer Chemother Pharmacol 2011 Feb 5;67(2):421-30. Epub 2010 May 5.

Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27D, 5117 Centre Avenue, Pittsburgh, PA 5213-1863, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1337-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954253PMC
February 2011

Coprescription of tamoxifen and medications that inhibit CYP2D6.

J Clin Oncol 2010 Jun 3;28(16):2768-76. Epub 2010 May 3.

Department of Oncology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.23.8931DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881853PMC
June 2010

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

Endocr Relat Cancer 2010 Sep 25;17(3):623-36. Epub 2010 Jun 25.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/ERC-09-0318DOI Listing
September 2010

Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.

Cancer Chemother Pharmacol 2010 Aug 11;66(3):575-83. Epub 2009 Dec 11.

Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-009-1198-z
Publisher Site
http://dx.doi.org/10.1007/s00280-009-1198-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931270PMC
August 2010

Endocrine therapy in 2009: consideration of the tumor and the host.

Oncology (Williston Park) 2009 Feb;23(2):150-1, 154

Department of Oncology, a Mayo Clinic College of Medicine Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
February 2009

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.

Mol Cancer Ther 2008 Apr;7(4):944-51

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745608PMC
April 2008

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.

Cancer Res 2007 Sep;67(18):8772-82

Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-0156DOI Listing
September 2007

Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.

Food Chem Toxicol 2008 Jan 10;46(1):203-11. Epub 2007 Aug 10.

Developmental Therapeutics Program, National Cancer Institute, Rm 8042, 6130 Executive Blvd., Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2007.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744343PMC
January 2008

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

Clin Colorectal Cancer 2007 May;6(7):516-21

Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2007.n.017DOI Listing
May 2007

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.

Clin Cancer Res 2006 Oct;12(20 Pt 1):6087-93

Department of Oncology, Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1015DOI Listing
October 2006

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

J Clin Oncol 2006 Jul;24(21):3423-30

Children's Hospital Los Angeles and the Department Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.03.9271DOI Listing
July 2006

LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).

J Chromatogr B Analyt Technol Biomed Life Sci 2006 Aug 24;840(1):56-62. Epub 2006 May 24.

Department of Oncology, Division of Developmental Oncology Research, Mayo Clinic and Foundation, 200 First Street S.W., Rochester, MN 55905, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2006.04.031DOI Listing
August 2006

Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.

Clin Cancer Res 2006 Jan;12(2):516-22

Division of Pharmacy, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1541DOI Listing
January 2006

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.

J Clin Oncol 2005 Dec;23(36):9179-86

Vanderbilt Children's Hospital, Pediatric Hematology/Oncology, Nashville TN 37232-6310, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.01.0660DOI Listing
December 2005

CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines.

Cancer Chemother Pharmacol 2006 May 11;57(5):569-76. Epub 2005 Aug 11.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Guggenheim 13, 200 First Street S.W., Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0075-7DOI Listing
May 2006

Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines.

Biochem Pharmacol 2005 Apr;69(8):1159-66

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic and Foundation, Guggenheim 13, 200 First Street S.W., Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2004.11.019DOI Listing
April 2005

Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model.

Mayo Clin Proc 2004 Mar;79(3):376-84

Department of Oncology Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4065/79.3.376DOI Listing
March 2004

The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes.

Clin Cancer Res 2004 Feb;10(4):1471-80

Department of Oncology and Mass Spectrometry Facility, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.ccr-0557-03DOI Listing
February 2004

Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice.

Cancer Chemother Pharmacol 2003 Jun 25;51(6):483-7. Epub 2003 Apr 25.

Division of Developmental Oncology Research, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://link.springer.de/link/service/journals/00280/contents
Publisher Site
http://dx.doi.org/10.1007/s00280-003-0570-7DOI Listing
June 2003

Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.

Cancer 2003 May;97(9 Suppl):2352-8

Division of Medical Oncology and Developmental Oncology Research, Cancer Center Statistics Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.11304
Publisher Site
http://dx.doi.org/10.1002/cncr.11304DOI Listing
May 2003

Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.

Clin Cancer Res 2002 Sep;8(9):2952-62

Department of Oncology, Division of Developmental Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
September 2002

A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

Clin Cancer Res 2002 Mar;8(3):712-7

Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
March 2002